Journal of Clinical Oncology Journal 8 Submit E-Alerts State of Clinical Oncology Journal

OpenAthens/Shibboleth »

ADVERTISEMENT

MENU

Article Tools

CANCERS OF THE COLON, RECTUM, AND ANUS

DNA damage response pathway mutations contribute to a high proportion of hereditary colorectal cancer in patients from the Republic of Macedonia.

<u>Marija Staninova</u>, <u>Nadica Matevska Geshkovska</u>, <u>Biljana</u> <u>Angelovska</u>, <u>Mitrevski Nenad</u>, <u>Milco Panovski</u>, <u>Aleksandar J</u> <u>Dimovski</u>

Show More

Abstract Disclosures

Abstract

512

Background: Hereditary factors are assumed to play a role in 35-45% of all colorectal cancers with 5%-10% associated with high penetrant disease-causing mutations in genes correlating to hereditary polyposis (HP) or hereditary nonpolyposis syndromes (HNPCC). Although inherited germline mismatch repair and *APC* gene mutations contribute significantly to CRC, still a genetic diagnosis cannot be obtained in > 50% of familial cases. **Methods:** We performed a targeted NGS sequencing of 103 probands with clinically diagnosed HP (39) or HNPCC (64) using a multigene panel on two different platforms (Illumina Cancer Panel and Ion Torrent custom

OPTIONS & TOOLS

Export Citation

Track Citation

Add To Favorites

Rights & Permissions

ADVERTISEMENT

COMPANION ARTICLES

No companion articles

ARTICLE CITATION

DOI:

10.1200/JCO.2019.37.4_suppl.512 Journal of Clinical Oncology 37, no. 4_suppl (February 01, 2019) 512-512.

Published online January 29, 2019.

WE RECOMMEND

Breast and Ovarian Cancer Penetrance Estimates Derived From Germline ADVERTISEMENT

panel) covering coding and exon/intron sequences of 100 genes implicated in hereditary cancers. Results: Overall, the molecular defect was identified in 60 (58%) index patients. As expected, a large percentage (82%) of these patients exhibited the presence of clearly pathogenic mutations in well-known genes associated with hCRC (APC, MUTYH, BMPR1A, NTHL1 in HP, MLH1, MSH2, PMS6, MSH6 in HNPCC). Surprisingly, all except one (FLCN c.1285dupC, detected in a family with classical FAP), of the remaining mutations were located in genes involved in the DNA damage response pathway, of which 3 in CHEK2 (c.1031delT; c.1229delC; c.599T>G), 2 in BRIP1 (c.2392C>T) and 1 in each of BLM (c.1642C>T), BRCA2 (c.4446_4451dupAACAGA), FANCM (c.2953delG), FH (c.1431_1433dupAAA) and ERCC2 (c.1403C>T). Clinically, six of these cases exhibited the HNPCC type X phenotype (mutations in BRCA2, BRIP1, FANCM and CHEK2) while the other four were classified as oligopolyposis (mutations in BLM, FH and CHEK2). Conclusions: Our data indicate a significant association of DNA damage response pathway deficiencies and carcinogenesis in patients with hCRC syndromes exhibiting either the HNPCC type X or oligopolyposis phenotype. No genetic defect was detected within the analyzed gene panel in 44 (42%) families, indicating the need of extended exome/whole genome analyses in a substantial portion of patients with this disease.

© 2019 by American Society of Clinical Oncology

Multiple-Gene Sequencing Results in Women Allison W. Kurian, JCO PO, 2017

Germline Cancer Susceptibility Mutations in Early-Onset Colorectal Cancer

By Matthew Stenger et al., Colorectal Cancer, 2017

Lower Incidence of Colorectal Cancer and Later Age of Disease Onset in 27 Families With Pathogenic MSH6 Germline Mutations Compared With Families With MLH1 or MSH2 Mutations: The German Hereditary Nonpolyposis Colorectal Cancer Consortium Jens Plaschke et al., J Clin Oncol, 2004

Selecting the Optimal Germline Genetic Test for Men With Prostate Cancer Is a Complex Choice ASCO Daily News, 2019

Population-Based Screening for Breast and Ovarian Cancer Genetic Mutations Appears Cost-Effective

By Jo Cavallo et al., Breast Cancer, 2018

240 First year experience of hereditary testing in gynecological cancer patients in a clinical setting in the bahamas S Bowe et al., International Journal of Gynecologic Cancer, 2019

One in three highly selected Greek patients with breast cancer carries a loss-of-function variant in a cancer susceptibility gene

Florentia Fostira et al., J Med Genet, 2020

Does multilocus inherited neoplasia alleles syndrome have severe clinical expression?

Agostina Stradella et al., J Med Genet, 2018

EP1029 A preliminary study of genetic susceptibility and treatment related